Activity from announced rounds
New Science Ventures is the investment firm named by Trellis and as lead in Novadip’s financing.
Novadip develops cell therapies and grafts for damaged tissue. Trellis develops human antibodies against difficult infectious diseases. The two companies pursue different therapeutic approaches under the same firm-level attribution.
A clinical-stage biotechnology company developing regenerative cell therapies and grafts to repair bone and other damaged tissues, including a pivotal-stage treatment for a rare pediatric bone disorder.
Developing native human monoclonal antibodies to treat intractable infectious diseases